Research, development, production and support for clinical trials ? Broadly neutralizing monoclonal antibodies (BNMABS)
Ended Awarded Last action
- Contract number
- HHSN26100019
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $27,524,748
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $27,524,748.20 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost No Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $49,826 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $67,104 | |
| Funding Only Action | $12,669,444 | |
| Other Administrative Action | $0 | |
| Original award | $14,738,374 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 19, 2016, with a ceiling value of $27,524,748.20 for research, development, production, and support for clinical trials of broadly neutralizing monoclonal antibodies (BNMAbs).
This delivery order is issued under a master indefinite delivery contract with NIAID. Place of performance is Frederick, MD. Ultimate completion is December 31, 2026. Pricing is cost, no fee.
The order funds clinical trial execution and manufacturing support for BNMAb therapeutic candidates, including Phase 1 and Phase 2 trial operations and production scale-up of monoclonal antibody assets. Service Contract Inventory reporting shows FY2021 invoicing of $470 thousand against 1.5 FTEs and 3,119 contractor hours at a derived government-paid rate of $150.60 per hour. The prime self-performed all reported hours with no subcontractors engaged on this order.
Quick answers
Who was awarded contract HHSN26100019?
HHSN26100019 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.
How much is contract HHSN26100019 worth?
The government has obligated $27,524,748 on HHSN26100019.
Which agency awarded contract HHSN26100019?
National Cancer Institute (National Institutes of Health) awarded HHSN26100019, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract HHSN26100019 an order under another contract?
Yes. HHSN26100019 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100019 competed?
The extent of competition for HHSN26100019 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award